Compare · CDMO vs NVO
CDMO vs NVO
Side-by-side comparison of Avid Bioservices Inc. (CDMO) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CDMO and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $203.51B, about 189.6x CDMO ($1.07B).
- NVO has hit the wire 13 times in the past 4 weeks while CDMO has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 9 for CDMO).
- Company
- Avid Bioservices Inc.
- Novo Nordisk A/S
- Price
- $12.50+0.16%
- $45.60+0.22%
- Market cap
- $1.07B
- $203.51B
- 1M return
- -
- +13.21%
- 1Y return
- -
- -36.22%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 13
- Recent ratings
- 9
- 25
Avid Bioservices Inc.
Avid Bioservices, Inc., a contract development and manufacturing organization, provides process development and current good manufacturing practices (CGMP) clinical and commercial manufacturing services focused on biopharmaceutical drug substances derived from mammalian cell culture. It produces monoclonal antibodies and recombinant proteins; and offers services, including CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, and regulatory submission and support. The company also provides various process development services, such as upstream and downstream development and optimization, analytical methods development, testing, and characterization. It serves biotechnology and pharmaceutical companies. The company was formerly known as Peregrine Pharmaceuticals, Inc. and changed its name to Avid Bioservices, Inc. in January 2018. Avid Bioservices, Inc. was incorporated in 1981 and is headquartered in Tustin, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CDMO
- SEC Form 15-12G filed by Avid Bioservices Inc.
- Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience
- V. P., General Counsel Ziebell Mark R returned 66,799 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Thoma Jeanne returned 45,611 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Sargen Gregory returned 36,368 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Operations Officer Richieri Richard A. returned 58,320 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Mackey Catherine J returned 43,379 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Commercial Officer Kwietniak Matthew R. returned 50,796 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Hart Daniel R returned 112,735 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Hancock Richard B returned 124,191 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates
- The Next Generation of the GLP-1 Revolution Is Already Underway